Browsing Tag

OPT302

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Eli Pacheco Jul 26, 2023 0

MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly…

Health

Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD…

Eli Pacheco Feb 13, 2023 0

…

Health

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV)…

Eli Pacheco Feb 14, 2022 0

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination…

Health

Opthea Granted Chinese Patent Covering OPT-302

Eli Pacheco Oct 26, 2021 0

MELBOURNE, Australia, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly…

Health

Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet…

Eli Pacheco Oct 4, 2021 0

MELBOURNE, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly…